GlassScriptPhysician profile
Marla Christine Current
NPI 1245450659
$2,935.03
in general payments reported to CMS, 2019-2025
29 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $135 · 2021: $130 · 2022: $242 · 2023: $277 · 2024: $349 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.19 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $802.81 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $358.37 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $245.57 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $177.06 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $152.52 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Pfizer INC. | $149.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.59 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $129.98 | 2021-2023 | Dexcom G7 Gss (161) |
| Exact Sciences Corporation | $98.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $91.04 | 2019-2025 | |
| Corium, LLC | $63.77 | 2025 | Azstarys |
| Dynavax Technologies Corporation | $55.63 | 2022-2025 | Heplisav-B |
| Astellas Pharma US INC | $45.47 | 2019 | |
| Sumitomo Pharma America, INC. | $43.97 | 2025 | Gemtesa |
| Lilly USA, LLC | $43.89 | 2019-2024 | Zepbound, Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $42.30 | 2025 | Rexulti |
| Shire North American Group INC | $39.62 | 2019 | |
| Lundbeck LLC | $33.17 | 2025 | Rexulti |
| Amarin Pharma, INC. | $31.46 | 2019-2021 | |
| Eisai INC. | $30.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.70 | 2019-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $25.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.32 | 2025 | Austedo Xr |
| Mayne Pharma Commercial LLC | $15.96 | 2024 | |
| Allergan, INC. | $12.23 | 2019 | |
| Merck Sharp & Dohme LLC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Current listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.